Pharmafile Logo
Pharmafocus logo
Advanced Search

MSD

Showing 15 posts of 247 posts found.

merck_incweb

MSD scores EU approval for Keytruda in lung cancer

August 3, 2016
Research and Development, Sales and Marketing EU, MSD, Merck, approval, keytruda, lung cancer

MSD, called Merck in the US and Canada, has announced that the European Commission has approved Keytruda (pembrolizumab) for patients …

News
merckwindow

400 current and former employees join sexual discrimination lawsuit against MSD

July 25, 2016
Research and Development, Sales and Marketing MSD, Merck, discrimination, lawsuit

Over 400 women have come forward to join a $250 million gender bias class action against MSD, called Merck in …

News
merckwindow

MSD faces delay in C. diff drug approval as FDA requests more data

July 22, 2016
Medical Communications, Research and Development C diff, FDA, MSD, Merck

MSD, known as Merck in the US and Canada, has received a setback in its bid to get new C. …

News
msd

UK medical charity sells part of interest in MSD’s Keytruda for $150 million

July 15, 2016
Research and Development, Sales and Marketing MSD, Merck, keytruda

UK medical research charity MRC Technology sold part of its royalty interest in US pharma major MSD’s (NYSE: MRK) immunotherapy …

News
msd

MSD gets CHMP positive opinion for keytruda to treat advanced lung cancer

June 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing CHMP, EMA, MSD, Merck & Co, keytruda, lung cancer

MSD (Merck & Co) said its anti-programmed death-1 (PD-1) therapy, Keytruda (pembrolizumab) to treat lung cancer has secured a positive …

News
merck

Merck & Co says Keytruda shows better results than chemotherapy in Phase III trials for lung cancer

June 17, 2016
Medical Communications MSD, Merck & Co, drug trial, keytruda, lung cancer

US drug major Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced non-small-cell …

News
merckincweb

MSD insulin glargine biosimilar meets primary endpoint in late-stage trials

June 14, 2016
Manufacturing and Production, Research and Development, Sales and Marketing MSD, Merck, biosimilar, insulin, insuline glargine

MSD (NYSE: MRK), known as Merck in the US and Canada, has announced results from two Phase III studies evaluating …

News

FDA committee recommends MSD’s c. diff prevention drug

June 10, 2016
Medical Communications, Research and Development, Sales and Marketing FDA, MSD, Merck, bezlotoxumab, committee, zinplava

The US Food and Drug Administration’s (FDA) antimicrobial drugs advisory committee has voted by 10 to 5, with one abstention, …

News
msd

MSD says Phase III trials for Keytruda to treat advanced melanoma shows better survival

June 8, 2016
Research and Development ASCO, MSD, Merck & Co, PD-L1, advanced melanoma, drug trial, immuno-oncology, keytruda

Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced melanoma showed over half …

News
merckwindow

MSD to collaborate with Fujifilm Diosynth on new microbial biologics facility

June 7, 2016
Manufacturing and Production, Research and Development MSD, Merck, fujifilm diosynth

MSD, known as Merck in the US and Canada, has entered into a collaboration with Fujifilm Diosynth Biotechnologies to invest …

News
gavel

Judge reverses verdict in MSD/Gilead hepatitis C dispute

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Gilead, MSD, Merck, dispute, patent, reversal, sovaldi

A US district judge has reversed a previous court decision which favoured MSD, called Merck in the US, over Gilead …

News

Trial data shows promise for Lilly/MSD combo regimen in lung cancer

June 6, 2016
Research and Development, Sales and Marketing MSD, Merck, collaboration, immuno-oncology, lilly, lung cancer, non-small cell, parternship

Eli Lilly (NYSE: LLY) has presented data at the American Society of Clinical Oncology (ASCO) annual congress showcasing its collaborations …

News
keytruda1

MSD receives fourth Breakthrough Therapy Designation for Keytruda

April 19, 2016
Manufacturing and Production, Research and Development Breakthrough Therapy Designation, FDA, Hodgkin lymphoma, MSD, Merck, breakthrough designation, breakthrough therapy, keytruda

MSD (NYSE: MRK) has announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation to Keytruda (pembrolizumab) …

News
msd

FDA accepts biologics license application for MSD’s allergy immunotherapy drug

April 13, 2016
Research and Development, Sales and Marketing MSD, Merck, allergy, dust mite, house, immunotherapy, mk-8237

MSD (NYSE: MRK) has announced that the US Food and Drug Administration has accepted for review the biologics license application …

News
msd

Gilead must pay MSD $200m in hep C drug patent case

March 29, 2016
Manufacturing and Production, Sales and Marketing Gilead Sciences, MSD, Solvadi, harvoni

A Californian federal jury has ordered Gilead Sciences to pay MSD and Ionis $200 million for infringing on patents relating …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025